The FDA last week approved AstraZeneca's SGLT2 inhibitor, Farxiga, to...

...reduce the risk of cardiovascular death and hospitalization in some patients, including those without diabetes. Farxiga was first approved to treat type 2 diabetes, a particularly crowded market, in 2014. For the treatment of type 2 diabetes under the pharmacy benefit, Farxiga currently holds preferred status for 32% of covered lives, growing to 58% with prior authorization and/or step therapy.

SOURCE: MMIT Analytics, as of 5/11/20